Indiana is currently home to 1256 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02464969
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Venous Thromboembolism
Register for Updates
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05508568
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: First Urology, Jeffersonville, Indiana
Conditions: Bladder Cancer
Register for Updates
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
NCT02397668
Recruiting
The Pivotal Study of the Cor TRICUSPID ECM Valve (or Cor PEDIATRIC Tricuspid ECM Valve). This study follows the EFS and is now to determine the safety and efficacy of the Cormatrix Cor TRICUSPID Valve for any patients requiring surgical replacement of the tricuspid valve.
Gender:
All
Ages:
Between 1 year and 70 years
Trial Updated:
01/25/2023
Locations: St Francis Hospital, Indianapolis, Indiana
Conditions: Tricuspid Valve Disease
Register for Updates
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
NCT05561764
Recruiting
There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex,... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
01/03/2023
Locations: IU Health University Hospital, Indianapolis, Indiana
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
NCT05314764
Recruiting
There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Cefiderocol is a newly approved broad spectrum intravenous siderophore cephalosporin antibiotic, which has potent in vitro activity against multidrug resistant Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter species, and Stenotrophomonas maltophilia, all pathogens implicated in CF pulmonary exacerbations. This study will deter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2022
Locations: IU Health University Hospital, Indianapolis, Indiana
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
A Bifido Bacteria to Improve Lactose Digestion and Tolerance
NCT05668468
Recruiting
We want to determine if feeding a bifido bacteria that readily digests lactose and galactooligosacharides improves lactose digestion and tolerance through alteration of the microbiome.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/20/2022
Locations: Purdue University, West Lafayette, Indiana
Conditions: Lactose Intolerance
Register for Updates
Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk
NCT05660278
Recruiting
Cow's milk contains two types of β-casein: A1 and A2. It is evident from human clinical trials that milk with A1 protein produces more hydrogen and symptoms of lactose intolerance. A pro-inflammatory μ-opioid peptide BCM-7 is released from A1 but not from A2. Milk containing A1 β-casein produced more inflammatory markers than A2 β-casein. This is a double-blinded, randomized, controlled trial conducted to determine if A1 beta-casein containing milk causes acute effects on inflammatory markers fo... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/20/2022
Locations: Purdue University, West Lafayette, Indiana
Conditions: Lactose Intolerance
Register for Updates
Cellular Scale Measures of Short-Term Retinal Atrophy Progression
NCT05643157
Recruiting
Our goal is to determine the cellular scale changes that occur in subjects who have disease progression due to pentosan polysulfate sodium toxicity
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
12/01/2022
Locations: Indiana University School of Optometry, Bloomington, Indiana
Conditions: Pentosan Polysulfate Sodium Maculopathy, Pigmentary Maculopathy, Toxic Maculopathy, Pigmentary Retinopathy, Interstitial Cystitis, Chronic
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Parkview Regional Medical Center, Fort Wayne, Indiana
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)
NCT04457752
Recruiting
A Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) and Standard of Care versus Standard of Care alone in the healing Chronic Diabetic Foot Ulcers. Multi-center, open label, randomized controlled trial. Study is estimated to require 12 months from first subject enrolled to last subject visit.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Hoosier Foot and Ankle, Fishers, Indiana
Conditions: Chronic Diabetic Foot Ulcers
Register for Updates
A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
NCT05535920
Recruiting
A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhythmias - ADAPT Trial
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2022
Locations: Nephrology Associates of Northern Illinois and Indiana (NANI), Fort Wayne, Indiana
Conditions: Hyperkalemia
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Indiana Spine Group, Carmel, Indiana
Conditions: Symptomatic Cervical Disc Disease
Register for Updates